Page 1

AILERON Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update August 11 , 2021 • Initiated Phase 1b randomized , double - blind , placebo - controlled trial of ALRN - 6924 in patients with advanced p53 - mutated non - small cell lung cancer ( NSCLC ) ; first interim safety data expected at end of 2021 and topline results mid - 2022 • Announces upcoming presentations to highlight final data from Aileron's completed Phase 1b trial of ALRN - 6924 in patients with small cell lung cancer ( SCLC ) and initial findings from ongoing Healthy Volunteer Study of ALRN - 6924 • ISEH 2021 Virtual Scientific Meeting ( August 25-28 , 2021 ) • ESMO Congress 2021 ( September 16-21 , 2021 ) • ALRN - 6924 is designed to deliver selective chemoprotection against chemotherapy - induced toxicities via p53 biomarker strategy • Nearly 1 million patients in the U.S. across all cancer types are diagnosed annually with p53 - mutated cancer • $ 59.5 million cash and cash equivalents as of June 30 , 2021 , expected to fund operations into second half of 2023 BOSTON , Aug. 11 , 2021 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( NASDAQ : ALRN ) , a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients , today reported business highlights and financial results for the second quarter ended June 30 , 2021 . " Bolstered by a strong balance sheet and a healthy cash runway , we continue to execute against our clinical development strategy to advance selective chemoprotection for patients with p53 - mutated cancer , including our initiation in the second quarter of our first randomized , double - blind , placebo - controlled clinical trial of ALRN - 6924 for patients with p53 - mutated non - small cell lung cancer ( NSCLC ) , " said Manuel Aivado , M.D. , Ph.D. , President and Chief Executive Officer at Aileron . Dr. Aivado continued , " The findings from this NSCLC trial will inform our late - stage clinical development strategy for ALRN - 6924 . Nearly 1 million cancer patients across all cancer types each year are diagnosed with p53 - mutated cancer in the United States alone , and chemotherapy continues to be a cornerstone of cancer treatment for nearly every patient . As such , we believe that ALRN - 6924 has the potential to protect many patients from chemotherapy - induced effects , thereby transforming their quality of life while they undergo chemotherapy and without reducing the effects of chemotherapy against cancer . " Aileron is developing ALRN - 6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations , which are present in over half of all cancer patients , to reduce or eliminate chemotherapy - induced side effects while not interfering with chemotherapy's attack on cancer cells . This novel concept is known as chemoprotection . By reducing or eliminating multiple chemotherapy - induced side effects , ALRN - 6924 may improve patients ' quality of life and help them better tolerate chemotherapy . Enhanced tolerability may lead to fewer dose reductions or delays of chemotherapy , which could result in an improved efficacy of chemotherapy . Given Aileron's p53 biomarker approach , designed to ensure selective chemoprotection only of healthy cells , coupled with the prevalence of p53 - mutated cancers , the company's strategy is to ultimately pursue a tumor- agnostic label for ALRN - 6924 as a chemoprotective agent in p53 - mutated cancers . Second Quarter 2021 Highlights and Recent Updates • Initiated randomized , double - blind , placebo - controlled Phase 1b clinical trial of ALRN - 6924 in patients with advanced NSCLC undergoing chemotherapy . Aileron anticipates enrolling a total of 60 patients with advanced